Carasent Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Daniel Ohman

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2yrs
CEO ownership	0.2%
Management average tenure	2yrs
Board average tenure	2.1yrs

Recent management updates

Recent updates

CEO

Daniel Ohman (44 yo)

2yrs

Tenure

Mr. Daniel Ohman was the Chief Executive Officer and President of GHP Specialty Care AB (publ) (formerly Global Health Partner AB (publ) since November 4, 2013 and served as its Business Area Manager of VG...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Svein Bjornstad	Chief Financial Officer	3.3yrs	no data	0.49% € 577.3k
Daniel Ohman	Chief Executive Officer	2yrs	no data	0.22% € 263.0k
Johan Eltes	Chief Technical Officer	2.1yrs	no data	no data
Jon Schultz	Legal Counsel	no data	NOK 45.00k	no data
Stefan Jernberg	Chief Compliance Officer	less than a year	no data	no data
Chris Damvakaris	Vice President of Sales & Business Development	no data	NOK 723.00k	no data
Cornelia Broqvist	Chief Marketing Officer	2.2yrs	no data	no data
Anna Larsson	People and Culture Manager	no data	no data	no data
Vilma Jonson	Head of Strategy	1.2yrs	no data	0.033% € 39.4k

2.0yrs

Average Tenure

Experienced Management: C34's management team is considered experienced (2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Tomas Meerits	Director	1.5yrs	no data	no data
Camilla Skoog	Independent Director	2.6yrs	no data	0.013% € 15.3k
Ulrika Sundling	Independent Director	2.6yrs	no data	0.028% € 32.6k
Petri Niemi	Independent Chairman of the Board	2.1yrs	no data	0.017% € 20.0k
Henric Carlsson	Independent Director	less than a year	no data	no data

2.1yrs

Average Tenure

54yo

Average Age

Experienced Board: C34's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Carasent Management

Management criteria checks 1/4

Key information

Recent management updates

High number of new and inexperienced directors

Carasent ASA Announces Changes to Its Board

Chief Executive Officer recently bought €121k worth of stock

Founder recently bought €2.4m worth of stock

High number of new and inexperienced directors

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Recent updates

Carasent ASA (OB:CARA) acquired Data - Al GmbH.

Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.06 loss in 3Q 2023)

New minor risk - Share price stability

High number of new and inexperienced directors

Eg Norge A/S cancelled the acquisition of Carasent ASA (OB:CARA).

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)

Chief Executive Officer recently bought €121k worth of stock

Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022)

Founder recently bought €2.4m worth of stock

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Carasent Asa Approves Dividend

Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022)

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Full year 2022 earnings released

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

High number of new and inexperienced directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: kr0.13 (vs kr0.28 loss in 3Q 2021)

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Second quarter 2022 earnings released: EPS: kr0.03 (vs kr0.34 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: kr0.32 (vs kr0.14 loss in 1Q 2021)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings released: kr0.002 loss per share (vs kr0.85 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)

Full year 2020 earnings released: kr0.85 loss per share (vs kr0.079 profit in FY 2019)

Aeternum Capital AS, a fund managed by Aeternum Management AS acquired 15% stake in Carasent ASA (OB:CARA).

Revenue misses expectations

New 90-day high: €3.76

Carasent ASA, Annual General Meeting, Jun 03, 2021

New 90-day high: €3.42

Carasent ASA Appoints Dennis Höjer as CEO

Carasent ASA (OB:CARA) acquired Avans Soma AS from Rieber & Søn ASA and others for approximately NOK 120 million.

New 90-day high: €2.59

Third quarter earnings released

Third quarter earnings released

Chairman recently sold €2.1m worth of stock

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age